- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03883594
Technology-Assisted Stepped Care Study (TASC Phase 3)
9. März 2022 aktualisiert von: Children's Hospital Medical Center, Cincinnati
Technology Assisted Stepped Care (TASC): Phase 3
The overall goal of this project is to demonstrate the feasibility, implementation, and preliminary efficacy of a technology-assisted stepped care (TASC) adherence-promotion intervention in adolescents with asthma.
This is the third phase (Phase 3) of a three-phase project to test the preliminary efficacy of a technology-assisted stepped care (TASC) intervention.
In Phase 1, we developed the intervention using patient and provider feedback from focus groups.
In Phase 2 we refined the developed intervention by having five adolescents from the focus groups test the intervention for feasibility.
In this third phase, we will enroll up to 50 adolescents to pilot-test the refined intervention for preliminary efficacy.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Up to fifty adolescents with asthma will be enrolled in an open label pilot trial of the TASC adherence-promotion intervention for a duration of twelve months.
First, participants will complete baseline questionnaires related to demographic, and clinical predictors of adherence and asthma and a 4 week run-in phase to assess baseline adherence using electronic inhaler monitoring with a cellphone that is provided to them.
Following the run-in period, all participants will receive Step 1 of the TASC intervention for a minimum of 4 weeks.
Step 1 (Information) will include electronic educational information related to asthma symptoms and triggers, attacks, self-monitoring, treatments, action plans, and automated text message medication reminders.
Following the initial four weeks of Step 1, adherence will be evaluated and a rate of less than 68% will serve as the cause for "stepping up" to the next level of the intervention.
Adherence checks will continue to occur every four weeks for the duration of the study and adherence <68% will prompt movement from one level of treatment to the next.
Participants may remain at a treatment level for more than four weeks and may complete 1, 2, or 3 interventions steps during the 5 month study depending on the adolescent's adherence.
Step 2 (Motivation) will include electronic monitoring of adherence and personally tailored feedback via text messages.
Adolescents will be given access to the adherence tracking cellphone app and graphs of their inhaler adherence.
Adolescents will also receive brief, personalized text messages that provide supportive motivation and directive, tangible actions.
Step 3 (Behavioral) will include problem-solving telehealth intervention with a trained clinician.
Four telehealth sessions individually tailored to the unique needs and barriers of the adolescent will be provided.
The primary outcome measure will be electronically-monitored adherence assessed at post-treatment.
Secondary outcomes include asthma severity as well as process evaluation questions and quantitative measures of feasibility, acceptability, and satisfaction to demonstrate implementation.
Participants will remain in the study for an additional 7 months after they complete month 5 of the study.
For the remaining 7 months, participants will be randomized to one of two booster session patterns with the goal to improve inhaler adherence.
The statistician will make the randomization schedule and the principle investigator will maintain the randomization schedule.
Two different booster patterns are being used to test which pattern will be most effective.
The first booster session pattern will include booster sessions at the end of month 6, 8, and 12.
The second booster session pattern will include booster sessions at the end of month 6, 7, 8, 10, and 12. Booster sessions will review content provided during the intervention and the intervention delivery method will be consistent with the participants final intervention step.
Participants will also continue to complete monthly check-ins with the study coordinator to complete the Composite Asthma Severity Index, the Asthma Control Test, and a spirometry test.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
40
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Medical Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
12 Jahre bis 18 Jahre (Kind, Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Patient age between 12-18 years
- Patient is diagnosed with severe-persistent or moderate-persistent asthma per NAEPP asthma guidelines
- Patient is prescribed at least one daily inhaled controller medication or a daily combination inhaled corticosteroid and long-acting beta-agonist and a beta-agonist bronchodilator
- English fluency for patient, caregiver, and clinician
Exclusion Criteria:
- Significant cognitive deficits that may interfere with comprehension per medical team or chart review.
- Diagnosis of serious mental illness (e.g., schizophrenia)
- Diagnosis of pervasive developmental disorder
- Active chronic disease apart from asthma or allergic disease (e.g. Bronchiectasis)
- Patient receives school administered daily controller medication at the time of the enrollment visit
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: TASC-Intervention
Alle Teilnehmer erhalten Schritt 1 der Intervention.
Teilnehmer, deren Einhaltung unter oder bei 68 % liegt, werden nach dem dritten oder vierten Monat der Studie zu Stufe 2 oder Stufe 3 aufsteigen.
|
Schritt 1 der Intervention umfasst Schulungsmaterialien zu Asthma.
Schritt 2 umfasst eine elektronische Überwachung der Einhaltung und eine auf den Teilnehmer persönlich zugeschnittene SMS-Intervention.
Schritt 3 umfasst telemedizinische Sitzungen zur Problemlösung mit einem ausgebildeten Kliniker.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Electronic Monitoring
Zeitfenster: 12 months
|
The Propeller Health monitoring system includes a Bluetooth enabled sensor that attaches to the patient's inhaler.
This sensor records every dose, or "puff", the patient takes and sends it to a corresponding online database that is accessible to study staff.
Participants will be given this sensor at baseline.
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Machbarkeits-/Akzeptanzfragebogen
Zeitfenster: 5 Monate
|
Am Ende jedes Schritts und am Ende der Studie erhalten die Teilnehmer in Form eines Fragebogens eine Bewertung von 5 bis 31 Punkten zu Format, Inhalt, Länge, Fähigkeiten und Akzeptanz der Intervention.
Der Bereich Machbarkeit liegt auf einer Skala von 0 bis 4, wobei 0 am schlechtesten und 4 am besten ist.
Der Fragebogen zur Akzeptanz reicht von „überhaupt nicht“ bis „sehr“, wobei „überhaupt nicht“ am schlechtesten und „sehr“ am besten ist.
|
5 Monate
|
|
System-Usability-Skala
Zeitfenster: 5 Monate
|
Am Ende jedes Schritts und am Ende der Studie erhalten die Teilnehmer eine 10-Punkte-Likert-Skala, die einen globalen Überblick über die Benutzerfreundlichkeit gibt, in Form eines Fragebogens.
Die Skala reicht von „Stimme überhaupt nicht zu“ bis „Stimme voll und ganz zu, wobei die Hälfte der Items umgekehrt bewertet wird.
|
5 Monate
|
|
Lung Function Assessment
Zeitfenster: Baseline assessment and then once a month for 12 months
|
The mobile spirometer records multiple parameters of the patient's lung function including forced expiratory volume, peak expiratory flow, forced vital capacity, and forced expiratory flow.
The spirometer sends the values to the corresponding mobile phone application, Propeller Health, which is directly accessible to the patient.
|
Baseline assessment and then once a month for 12 months
|
|
Composite Asthma Severity Index (CASI)
Zeitfenster: Baseline assessment and then once a month for 12 months
|
The participants' composite asthma severity index score will be calculated through the TreatSmart program.
TreatSmart will be used to determine the participant's symptom burden, health care utilization, systemic corticosteroid use, and current medication use to determine the level of asthma severity/control the participant has.
The program also makes an initial treatment recommendation based on the National Asthma Education and Prevention Program (NAEPP asthma guidelines).
Individuals are placed in Step 1 through Step 6 depending on the strength and frequency of their inhaled corticosteroid (1 being low dose and 6 being a high dose).
In addition, individuals are categorized as very poorly controlled, not well controlled, or well controlled based on how frequently they have had asthma symptoms or used their rescue inhaler, gone to the hospital or urgent care, or received steroids for asthma symptoms.
|
Baseline assessment and then once a month for 12 months
|
|
Asthma Control Test (ACT)
Zeitfenster: Baseline assessment and then once a month for 12 months
|
The ACT will be used as a measure of disease severity in this study.
The ACT is a 5-question scoring tool designed for patients with asthma who are 12 years and older.
The questions ask the patient to rate their asthma severity, symptom frequency, control, and inhaler use on a scale of 1-5.
The total score is calculated by the sum of each response, which determines how well-controlled the patient's asthma is on a scale from 5-25.
|
Baseline assessment and then once a month for 12 months
|
|
Attendance/Participation rates
Zeitfenster: 12 months
|
Participation rates will be measured 3 different ways.
The first measure will be how often participants accessed the electronic material (educational materials and/or Propeller Health app), the second measure will be how many responses to directive text messaging were received, and the third measure will be attendance to the telehealth sessions.
|
12 months
|
|
Acceptability of Intervention Measure (AIM)
Zeitfenster: At 5 months
|
A 4 item measure of participants' belief that the intervention is acceptable will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
|
Intervention Appropriateness Measure (IAM)
Zeitfenster: At 5 months
|
A 4 item measure of participants' perception that the intervention is appropriate will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
|
Feasibility of Intervention Measure (FIM)
Zeitfenster: At 5 months
|
A 4 item measure of participants' belief that the intervention is feasible will be given at the end of the study.
Participants respond to each statement on a 5 point Likert scale (1= Completely Disagree, 5= Completely Agree).
|
At 5 months
|
|
Treatment Fidelity
Zeitfenster: 12 months
|
Treatment fidelity needed for the intervention will be assessed.
Treatment fidelity will be assessed through fidelity checklists created specifically for each intervention session.
|
12 months
|
|
Time Needed for Intervention
Zeitfenster: 12 months
|
Sessions will be timed and the number of weeks to complete the session will be tracked to determine the average length of time needed for the intervention.
|
12 months
|
|
Perceived Characteristics of Intervention Scale
Zeitfenster: At 12 months
|
19 item measure of interventionist views toward the study intervention.
|
At 12 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Behavior Assessment System for Children-Third Edition, Self-report of Personality (BASC-3-SRP-A
Zeitfenster: Baseline assessment and at 5 months
|
The BASC-3 is a widely used, reliable (α= 0.94 - 0.96 , test-retest r= 0.81 -0.82), and valid inventory to assess emotional and behavioral symptoms in adolescents and young adults (ages 13-21).
|
Baseline assessment and at 5 months
|
|
Adolescent Barriers to Medication Scales (AMBS)
Zeitfenster: Baseline Assessment
|
The AMBS is an 18-item validated measure of perceived barriers to medication adherence in adolescents.
|
Baseline Assessment
|
|
Technology-based Experience of Need Satisfaction- Interface questionnaire (TENS-Interface)
Zeitfenster: Baseline assessment and then at 2 months
|
A 15- item measure of participant's competence, autonomy, and relatedness in using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
|
Autonomy and Competence in Technology Adoption Questionnaire (ACTA)
Zeitfenster: Baseline Assessment
|
A 10-item measure of why people adopt use of a technology (i.e.
download an app, register with a website, purchase a wearable device, etc.).Participants respond to self-regulation statements on a scale of 1 to 5, 1 being 'not at all true' and 5 being 'very true.'
|
Baseline Assessment
|
|
Technology-based Experience of Need Satisfaction- Task questionnaire (TENS- Task)
Zeitfenster: Baseline assessment and then at 2 months
|
An 8-item measure of participant's competence, autonomy, and relatedness in managing their asthma using technology.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
|
Technology Effects on Need Satisfaction in Life (TENS- Life)
Zeitfenster: Baseline assessment and then at 2 months
|
The TENS-Life is a 10- item measure of the extent to which a user perceives that the use of a particular technology has had an influence on the satisfaction of basic psychological needs in their life.
Participants rate their level of agreement to each statement on a 5- point Likert scale (1= Do Not Agree, 5= Strongly Agree).
|
Baseline assessment and then at 2 months
|
|
Wissensfragebogen
Zeitfenster: Basisbewertung
|
Ein 13-Punkte-Fragebogen, der das Wissen des Einzelnen über Asthmasymptome, Auslöser und Medikamente bewertet.
Die Teilnehmer bewerten den Grad ihrer Zustimmung zu jeder Aussage auf einer Skala von „stimme völlig zu“ bis „stimme überhaupt nicht zu“.
Dieser Fragebogen wird beim Basisbesuch ausgefüllt.
|
Basisbewertung
|
|
Härtefallfragebogen
Zeitfenster: Basisbewertung
|
Ein validierter Fragebogen mit 19 Punkten, der die finanzielle Belastung von Einzelpersonen innerhalb eines Haushalts bewertet.
|
Basisbewertung
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
7. Dezember 2018
Primärer Abschluss (Tatsächlich)
20. April 2021
Studienabschluss (Tatsächlich)
20. April 2021
Studienanmeldedaten
Zuerst eingereicht
8. Februar 2019
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
19. März 2019
Zuerst gepostet (Tatsächlich)
21. März 2019
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
10. März 2022
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
9. März 2022
Zuletzt verifiziert
1. März 2022
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- CIN001- {"TASC Phase 3"}
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
UNENTSCHIEDEN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .